Squalene: A natural triterpene for use in disease management and therapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Gershenzon, 2007, The function of terpene natural products in the natural world, Nat. Chem. Biol., 3, 408, 10.1038/nchembio.2007.5
Penuelas, 2005, Isoprenoids: an evolutionary pool for photoprotection, Trends Plant Sci., 10, 166, 10.1016/j.tplants.2005.02.005
Ourisson, 1989, The evolution of terpenes to sterols, Pure Appl. Chem., 61, 345, 10.1351/pac198961030345
Hammer, 2003, Antifungal activity of the components of Melaleuca alternifolia (tea tree) oil, J. Appl. Microbiol., 95, 853, 10.1046/j.1365-2672.2003.02059.x
Friedman, 2004, Antibacterial activities of plant essential oils and their components against Escherichia coli O157:H7 and Salmonella enterica in apple juice, J. Agric. Food Chem., 52, 6042, 10.1021/jf0495340
Moore, 1993, Squalamine: an aminosterol antibiotic from the shark, Proc. Natl. Acad. Sci. U. S. A., 90, 1354, 10.1073/pnas.90.4.1354
Trombetta, 2005, Mechanisms of antibacterial action of three monoterpenes, Antimicrob. Agents Chemother., 49, 2474, 10.1128/AAC.49.6.2474-2478.2005
Robledo, 2005, In vitro and in vivo cytotoxicities and antileishmanial activities of thymol and hemisynthetic derivatives, Antimicrob. Agents Chemother., 49, 1652, 10.1128/AAC.49.4.1652-1655.2005
Kiuchi, 2002, Monoterpene hydroperoxides with trypanocidal activity from Chenopodium ambrosioides, J. Nat. Prod., 65, 509, 10.1021/np010445g
Ikeda, 2005, Anti-herpes virus type 1 activity of oleanane-type triterpenoids, Biol. Pharm. Bull., 28, 1779, 10.1248/bpb.28.1779
Armaka, 1999, Antiviral properties of isoborneol, a potent inhibitor of herpes simplex virus type 1, Antiviral Res., 43, 79, 10.1016/S0166-3542(99)00036-4
Jeppesen, 2000, Stevioside acts directly on pancreatic β cells to secrete insulin: actions independent of cyclic adenosine monophosphate and adenosine triphosphate-sensitive K+-channel activity, Metabolism, 49, 208, 10.1016/S0026-0495(00)91325-8
Look, 1986, The pseudopterosins: anti-inflammatory and analgesic natural products from the sea whip Pseudopterogorgia elisabethae, Proc. Natl. Acad. Sci. U. S. A., 83, 6238, 10.1073/pnas.83.17.6238
Look, 1986, The pseudopterosins: a new class of anti-inflammatory and analgesic diterpene pentosides from the marine sea whip Pseudoptergorgia elisabethae (Octocorallia), J. Org. Chem., 51, 5140, 10.1021/jo00376a016
Peana, 2002, Anti-inflammatory activity of linalool and linalyl acetate constituents of essential oils, Phytomedicine, 9, 721, 10.1078/094471102321621322
Otuki, 2005, Topical antiinflammatory effects of the ether extract from Protium kleinii and alpha-amyrin pentacyclic triterpene, Eur. J. Pharmacol., 507, 253, 10.1016/j.ejphar.2004.11.012
Shi, 2002, Induction of cytostasis in mammary carcinoma cells treated with the anticancer agent perillyl alcohol, Carcinogenesis, 23, 131, 10.1093/carcin/23.1.131
Wiseman, 2007, Cell cycle arrest by the isoprenoids perillyl alcohol, geraniol, and farnesol is mediated by p21(Cip1) and p27(Kip1) in human pancreatic adenocarcinoma cells, J. Pharmacol. Exp. Ther., 320, 1163, 10.1124/jpet.106.111666
Reddy, 1997, Chemoprevention of colon carcinogenesis by dietary perillyl alcohol, Cancer Res., 57, 420
Sgadari, 2000, Mechanism of paclitaxel activity in Kaposi's sarcoma, J. Immunol., 165, 509, 10.4049/jimmunol.165.1.509
Gidding, 1999, Vincristine revisited, Crit. Rev. Oncol. Hematol., 29, 267, 10.1016/S1040-8428(98)00023-7
van der Heijden, 2004, The Catharanthus alkaloids: pharmacognosy and biotechnology, Curr. Med. Chem., 11, 607, 10.2174/0929867043455846
O'Connor, 2006, Chemistry and biology of monoterpene indole alkaloid biosynthesis, Nat. Prod. Rep., 23, 532, 10.1039/b512615k
Guthmann, 2008, Assessing antimalarial efficacy in a time of change to artemisinin-based combination therapies: the role of Médecins Sans Frontiers, PLoS Med., 5, 1191, 10.1371/journal.pmed.0050169
Kelly, 1999, Squalene and its potential clinical uses, Altern. Med. Rev., 4, 29
Liu, 1976, Measurement of squalene in human tissues and plasma: validation and application, J. Lipid Res., 17, 38, 10.1016/S0022-2275(20)37014-0
Newmark, 1997, Squalene, olive oil, and cancer risk: a review and hypothesis, Cancer Epidemiol. Biomarkers Prev., 6, 1101
Koivisto, 1988, Increased amount of cholesterol precursors in lipoproteins after ileal exclusion, Lipids, 23, 993, 10.1007/BF02536349
Stewart, 1992, Sebaceous gland lipids, Semin. Dermatol., 11, 100
Tilvis, 1982, Fate of intravenously administered squalene in the rat, Biochim. Biophys. Acta, 712, 374, 10.1016/0005-2760(82)90355-1
Relas, 2001, Fate of intravenously administered squalene and plant sterols in human subjects, J. Lipid Res., 42, 988, 10.1016/S0022-2275(20)31623-0
Miettinen, 1994, Serum concentration and metabolism of cholesterol during rapeseed oil and squalene feeding, Am. J. Clin. Nutr., 59, 356, 10.1093/ajcn/59.2.356
Gylling, 1994, Post absorptive metabolism of dietary squalene, Atherosclerosis, 106, 169, 10.1016/0021-9150(94)90122-8
Tilvis, 1983, Absorption and metabolic fate of dietary 3H-squalene in the rat, Lipids, 18, 233, 10.1007/BF02534554
Strandberg, 1983, Sterol synthesis from biliary squalene in the jejunal mucosa of the rat in vivo, Lipids, 18, 530, 10.1007/BF02535392
Tilvis, 1983, Dietary squalene increases tissue sterols and fecal bile acids in the rat, Lipids, 18, 32, 10.1007/BF02534687
Sotiroudis, 2008, Anticarcinogenic compounds of olive oil and related biomarkers, Eur. J. Nutr., 47, 69, 10.1007/s00394-008-2008-9
Whittenton, 2008, Evaluation of asymmetric liposomal nanoparticles for encapsulation of polynucleotides, Langmuir, 24, 8533, 10.1021/la801133j
Tadrosa, 2004, Formation and stability of nano-emulsions, Adv. Colloid Interface Sci., 108–109, 303, 10.1016/j.cis.2003.10.023
Fox, 2008, Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions, Colloids Surf., B Biointerfaces, 65, 98, 10.1016/j.colsurfb.2008.03.003
Mesa, 2004, L.E, Fernandez Challenges facing adjuvants for cancer immunotherapy, Immunol. Cell Biol., 82, 644, 10.1111/j.0818-9641.2004.01279.x
Gupta, 1995, G.R. Siber, 229
Potter, 1962, Plasmacell neoplasia in single host: a mosaic of difterent protein producing cell types, J. Exp. Med., 115, 339, 10.1084/jem.115.2.339
Bingham, 1967, The effects of repeated injections of certain adjuvants on chemical carcinogenesis, Ann. Allergy, 25, 684
Hilleman, 1972, Studies for safety of adjuvant 65, Ann. Allergy, 30, 477
Allison, 1986, An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity, J. Immunol. Methods, 95, 157, 10.1016/0022-1759(86)90402-3
Wintsch, 1991, Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine, J. Infect. Dis., 163, 219, 10.1093/infdis/163.2.219
Lidgate, 1995, N.E. Byars, 313
R.N. Hjorth, Adjuvants for Viral Vaccines, U.S. Patent 5, 690, 942 (1997).
R.N. Hjorth, Adjuvants for Viral Vaccines, U.S. Patent 5, 718, 904 (1998).
Del Giudice, 2006, Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene, Clin. Vaccine Immunol., 13, 1010, 10.1128/CVI.00191-06
Podda, 2004, MF59 adjuvant emulsion, 225
Sesardic, 2004, European union regulatory developments for new vaccine adjuvants and delivery systems, Vaccine, 22, 2452, 10.1016/j.vaccine.2003.11.071
O'Hagan, 2007, MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection, Exp. Rev. Vaccines, 6, 699, 10.1586/14760584.6.5.699
O'Hagan, 2007, MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?, Clin. Pharmacol. Ther., 82, 740, 10.1038/sj.clpt.6100402
Ebensen, 2008, Immune modulators with defined molecular targets, Hum. Vacc., 4, 13, 10.4161/hv.4.1.5560
Allison, 1999, Squalene and squalane emulsions as adjuvants, Methods, 19, 87, 10.1006/meth.1999.0832
Seubert, 2008, The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells, J. Immunol., 180, 5402, 10.4049/jimmunol.180.8.5402
Byars, 1991, Improvement of hepatitis B vaccine by the use of a new adjuvant, Vaccine, 9, 309, 10.1016/0264-410X(91)90056-C
Hsu, 1997, Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long-term results of a clinical trial, Blood, 89, 3129, 10.1182/blood.V89.9.3129
Quan, 1997, Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m, J. Clin. Oncol., 15, 2103, 10.1200/JCO.1997.15.5.2103
Suli, 2004, Experimental squalene adjuvant. I. Preparation and testing of its effectiveness, Vaccine, 22, 3464
Benisek, 2004, Experimental squalene adjuvant II. Harmlessness and local reactogenity, Vaccine, 22, 3470, 10.1016/j.vaccine.2004.02.024
Hilgers, 1994, A novel non-mineral oil-based adjuvant. I. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in laboratory animals, Vaccine, 12, 653, 10.1016/0264-410X(94)90272-0
Hilgers, 1999, Sulfolipo-cyclodextrin in squalane-in-water as a novel and safe vaccine adjuvant, Vaccine, 17, 219, 10.1016/S0264-410X(98)00195-9
Mathews, 1992, Sharks still intrigue cancer researchers. News report, J. Natl. Cancer Inst., 84, 1000, 10.1093/jnci/84.13.1000-a
Liu, 1976, Measurement of squalene in human tissues and plasma: validation and application, J. Lipid Res., 17, 38, 10.1016/S0022-2275(20)37014-0
Trichopoulou, 1993, The macronutrient composition of the Greek diet: estimates derived from six case-control studies, Eur. J. Clin. Nutr., 47, 549
Owen, 2000, Olive-oil consumption and health: the possible role of antioxidants, Lancet Oncol., 1, 107, 10.1016/S1470-2045(00)00015-2
Owen, 2004, Olives and olive oil in cancer prevention, Eur. J. Cancer Prev., 13, 319, 10.1097/01.cej.0000130221.19480.7e
Smith, 2000, Squalene: potential chemopreventive agent, Exp. Opin. Invest. drugs, 9, 1841, 10.1517/13543784.9.8.1841
Van Duuren, 1976, Co-carcinogenic and tumor-promoting agents in tobacco carcinogenesis, J. Natl. Cancer Inst., 56, 1237, 10.1093/jnci/56.6.1237
Murakoshi, 1992, Inhibition by squalene of the tumor-promoting activity of 12-0-tetradecanoylphorbol-13-acetate in mouse-skin carcinogenesis, Int. J. Cancer, 52, 950, 10.1002/ijc.2910520620
Bos, 1989, ras oncogenes in human cancer: a review, Cancer Res., 49, 4682
Kate, 1992, Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity, Proc. Natl. Acad. Sci. U. S. A., 89, 6403, 10.1073/pnas.89.14.6403
Yarkoni, 1979, Tumor regression after intralesional injection of mycobacterial components emulsified in 2, 6, 10, 15, 19, 23-hexamethyl-2, 6, 10, 14, 18, 22-tetracosahexaene (squalene), 2, 6, 10, 15, 19, 23-hexamethyltetracosane (squalane), peanut oil, or mineral oil, Cancer Res., 39, 1518
Yarkoni, 1982, Eradication by active specific immunotherapy of established tumor transplants and microscopic lymph node metastases, Cancer Res., 42, 2544
Pim, 1980, Suppression of an ascitic rat hepatoma with cord factor and Nocardia cell wall skeleton in squalene emulsions, Eur. J. Cancer, 16, 1645, 10.1016/0014-2964(80)90043-2
Koyha, 1986, Antitumor effect of a synthetic cord factor, 6, 6'-di-O-decanoyl-alpha, alpha-trehalose (SS554), in mice, Jpn. J. Cancer Res., 77, 602
Nakagawa, 1985, Potentiation by squalene of the cytotoxicity of anticancer agents against cultured mammalian cells and murine tumor, Jpn. J. Cancer Res., 76, 315
Yamaguchi, 1985, Potentiation by squalene of antitumor effect of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-nitros ourea in a murine tumor system, Jpn. J. Cancer Res., 76, 1021
Auffray, 2007, Protection against singlet oxygen, the main actor of sebum squalene peroxidation during sun exposure, using Commiphora myrrha essential oil, Int. J. Cosmet. Sci., 29, 23, 10.1111/j.1467-2494.2007.00360.x
Yarkoni, 1979, Tumor regression after intralesional injection of mycobacterial components emulsified in 2, 6, 1O, 15, 19, 23-hexamethyl-2, 6, 1O, 14, 18, 22-tetracosahexaene (squalene), 2, 6, 10, 15, 19, 23-hexamethyltetracosane (squalane), peanut oil, or mineral oil, Cancer Res., 39, 1518
Desai, 1996, The preventive and therapeutic potential of the squalene-containing compound, Roidex, on tumor promotion and regression, Cancer Lett., 101, 93, 10.1016/0304-3835(96)04122-5
Rao, 1998, Chemopreventive effect of squalene on colon cancer, Carcinogenesis, 19, 287, 10.1093/carcin/19.2.287
Katdare, 1997, Prevention of mammary preneoplastic transformation by naturally occurring tumor inhibitors, Cancer Lett., 111, 141, 10.1016/S0304-3835(96)04523-5
Scolastici, 2004, Squalene does not exhibit a chemopreventive activity and increases plasma cholesterol in a Wistar rat hepatocarcinogenesis model, Nutr. Cancer, 50, 101, 10.1207/s15327914nc5001_13
Smith, 1998, G.Y. Yang, D.N. Seril, J. Liao, S. Kim, Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis by dietary olive oil and squalene, Carcinogenesis, 19, 703, 10.1093/carcin/19.4.703
Das, 2003, In vitro cytoprotective activity of squalene on a bone marrow versus neuroblastoma model of cisplatin-induced toxicity: implications in cancer chemotherapy, Eur. J. Cancer, 39, 2556, 10.1016/j.ejca.2003.07.002
Das, 2008, Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth, Neoplasia, 10, 1105, 10.1593/neo.08466
Senthilkumar, 2006, Effect of squalene on cyclophosphamide-induced toxicity, Clin. Chim. Acta, 364, 335, 10.1016/j.cca.2005.07.032
Senthilkumar, 2006, Attenuation of cyclophosphamide induced toxicity by squalene in experimental rats, Chem. Biol. Interact., 160, 252, 10.1016/j.cbi.2006.02.004
Nowicki, 2007, Shark liver oil as a supporting therapy in atopic dermatitis, Pol. Merkuriusz. Lek., 22, 312
Kohno, 1995, Kinetic study of quenching reaction of singlet oxygen and scavenging reaction of free radical by squalene in n-butanol, Biochim. Biophys. Acta, 1256, 52, 10.1016/0005-2760(95)00005-W
Hashim, 2005, Components of olive oil and chemoprevention of colorectal cancer, Nutr. Rev., 63, 374, 10.1111/j.1753-4887.2005.tb00374.x
Aioi, 1995, Effect of squalene on superoxide anion generation induced by a skin irritant, lauroylsarcosine, Int. J. Pharm., 113, 159, 10.1016/0378-5173(94)00190-G
Buddhan, 2007, Protective effect of dietary squalene supplementation on mitochondrial function in liver of aged rats, Prostaglandins Leukot. Essent. Fat. Acids, 76, 349, 10.1016/j.plefa.2007.05.001
Sabeena Farvin, 2004, Effect of squalene on tissue defense system in isoproterenol-induced myocardial infarction in rats, Pharmacol. Res., 50, 231, 10.1016/j.phrs.2004.03.004
Couvreur, 2006, Nanotechnology: intelligent design to treat complex disease, Pharm. Res., 23, 1417, 10.1007/s11095-006-0284-8
Soppimath, 2001, Biodegradable polymeric nanoparticles as drug delivery devices, J. Control. Release, 70, 1, 10.1016/S0168-3659(00)00339-4
Wang, 2008, The delivery and antinociceptive effects of morphine and its ester prodrugs from lipid emulsions, Int. J. Pharm., 353, 95, 10.1016/j.ijpharm.2007.11.013
Wang, 2006, Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs, J. Control. Rel., 115, 140, 10.1016/j.jconrel.2006.07.023
Fang, 2008, Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC), Eur. J. Pharm. Biopharm., 70, 633, 10.1016/j.ejpb.2008.05.008
Alexander, 2005, Lipid nucleoside conjugates for the treatment of cancer, Curr. Pharm. Des., 11, 1079, 10.2174/1381612053507602
Bergman, 2004, Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines, Biochem. Pharmacol., 67, 503, 10.1016/j.bcp.2003.09.028
Ali, 2005, Synthesis and biological evaluation of gemcitabine-lipid conjugate (NEO6002), Bioorg. Med. Chem. Lett., 15, 2571, 10.1016/j.bmcl.2005.03.046
Chen, 2006, In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate, Anticancer Drugs, 17, 53, 10.1097/01.cad.0000185182.80227.48
Adema, 2007, Troxacitabine prodrugs for pancreatic cancer, Nucleosides Nucleotides Nucleic Acids, 26, 1073, 10.1080/15257770701515591
Couvreur, 2006
Payne, 2006, DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial, J. Thorac. Oncol., 1, 984, 10.1097/01243894-200611000-00011
Jones, 2008, A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma, Cancer Chemother. Pharmacol., 61, 435, 10.1007/s00280-007-0486-8
Dueland, 2009, Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study, Acta Oncol., 48, 137, 10.1080/02841860802183620
Couvreur, 2006, Squalenoyl nanomedicines as potential therapeutics, Nano Lett., 6, 2544, 10.1021/nl061942q
Reddy, 2008, Novel approaches to deliver gemcitabine to cancers, Curr. Pharm. Des., 14, 1124, 10.2174/138161208784246216
Hertel, 1990, Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′-deoxycytidine), Cancer Res., 50, 4417
Plunkett, 1995, Preclinical characteristics of gemcitabine, Anticancer Drugs, 6, 7, 10.1097/00001813-199512006-00002
Reid, 2004, Phase I trial and pharmacokinetics of germcitabine in children with advanced solid tumors, J. Clin. Oncol., 22, 2445, 10.1200/JCO.2004.10.142
Couvreur, 2008, Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue, Small, 4, 247, 10.1002/smll.200700731
Reddy, 2008, Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine, J. Pharmacol. Exp. Ther., 325, 484, 10.1124/jpet.107.133751
Reddy, 2007, A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types, J. Control. Release, 124, 20, 10.1016/j.jconrel.2007.08.018
Bekkara-Aounallah, 2008, Novel pegylated nanoassemblies made of self-assembled squalenoyl nucleoside analogues, Adv. Funct. Mater., 18, 3715, 10.1002/adfm.200800705
Reddy, 2008, Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms, Anticancer Drugs, 19, 999, 10.1097/CAD.0b013e3283126585
Reddy, 2008, Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice, Drug Metab. Dispos., 36, 1570, 10.1124/dmd.108.020735
Arias, 2008, Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting, Langmuir, 24, 7512, 10.1021/la800547s
Saudek, 1978, Plasma squalene: lipoprotein distribution and kinetic analysis, J. Lipid Res., 19, 827, 10.1016/S0022-2275(20)40695-9
Chung, 2001, Oil components modulate physical characteristics and function of the natural oil emulsions as drug or gene delivery system, J. Control. Rel., 71, 339, 10.1016/S0168-3659(00)00363-1
Kim, 2003, The effects of serum on the stability and the transfection activity of the cationic lipid emulsion with various oils, Int. J. Pharm., 252, 241, 10.1016/S0378-5173(02)00676-2
Kwon, 2008, In vivo time-dependent gene expression of cationic lipid-based emulsion as a stable and biocompatible non-viral gene carrier, J. Control. Rel., 128, 89, 10.1016/j.jconrel.2008.02.004
Asa, 2000, Antibodies to squalene in Gulf War Syndrome, Exp. Mol. Pathol., 68, 55, 10.1006/exmp.1999.2295
Asa, 2002, Antibodies to squalene in recipients of anthrax vaccine, Exp. Mol. Pathol., 73, 19, 10.1006/exmp.2002.2429
Matyas, 2000, Induction and detection of antibodies to squalene, J. Immunol. Methods, 245, 1, 10.1016/S0022-1759(00)00268-4
Matyas, 2004, Detection of antibodies to squalene III. Naturally occurring antibodies to squalene in humans and mice, J. Immunol. Methods, 286, 47, 10.1016/j.jim.2003.11.002
Satoha, 2003, Induction of lupus autoantibodies by adjuvants, J. Autoimmun., 21, 1, 10.1016/S0896-8411(03)00083-0
Kuroda, 2004, Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine, Biomed. Pharmacother., 58, 325, 10.1016/j.biopha.2004.04.009